MedTrace Logo

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

NCT00003681 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2009-05-12

No results posted yet for this study

Summary

RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia in patients with myelodysplastic syndrome.

PURPOSE: Phase II trial to study the effectiveness of amifostine with or without epoetin alfa in treating patients who have myelodysplastic syndrome.

Conditions

Interventions

BIOLOGICAL

epoetin alfa

DRUG

amifostine trihydrate

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Roel Willemze, MD, PhD · Leiden University Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31

Countries

  • Austria
  • Belgium
  • Czechia
  • Netherlands
  • Portugal
  • Slovakia
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003681 on ClinicalTrials.gov